# PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response

> **NCT03098862** · — · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 4830 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03098862
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-04
- **Primary completion:** 2019-02-28
- **Final completion:** 2020-12-23
- **Target enrollment:** 4830 (ACTUAL)
- **Last updated:** 2022-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03098862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03098862, "PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03098862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*